To determine if GLUT5 conferred a metabolic benefit to CAR-T cells in vivo, we evaluated the anti-tumour function of GLUT5-expressing CAR-T cells in our well-established preclinical model of AML (Fig. 6A).24 Immunodeficient mice were transplanted with CBG-expressing Molm14 cells. Here, SLC2A5 is linked to neoplasm.